Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
Clinical trial NCT03043872 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03043872
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-27
- Primary completion
- 2020-01-27
- Enrollment
- 987
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.